66.61USDMkt Cap: 2.25B USDP/E: —Last update: 2026-05-22
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap2.25B USD
Enterprise Value1.27B USD
Revenue (TTM)55.63M USD
Gross Profit55.23M USD
Net Income (TTM)-164.08M USD
Revenue/Share2.847 USD
Last Price66.61 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees63
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS6402681083
Valuation
P/E (Trailing)—
P/E (Forward)-5.46
PEG0.31
EV/EBITDA-10.27
EV/Revenue22.85
P/S41.65
P/B2.94
EPS (TTM)-7.93
EPS (Forward)-12.56
52W Range
66.446% of range69.21
52W High69.21 USD
52W Low66.44 USD
Profitability
Gross Margin100.00%
Oper. Margin-352.25%
EBITDA Margin-222.54%
Profit Margin-297.07%
ROE-182.65%
ROA-58.51%
Growth
Revenue Growth3.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-208.51M USD
CapEx (TTM)171.00K USD
FCF Margin—
FCF Yield—
Net Debt-425.17M USD
Net Debt/EBITDA3.43
Balance Sheet
Debt/Equity0.95
Current Ratio10.21
Quick Ratio9.85
Book Value/Sh23.30 USD
Cash/Share22.99 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateJun 9, 2025
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)153.25 USD
Target Range80.00 USD – 192.00 USD
# Analysts8
Ownership
Shares Out.33.79M
Float21.33M
Insiders0.45%
Institutions79.99%
Short Interest
Short Ratio3.4d
Short % Float13.40%
Short % Out.12.14%
Shares Short4.10M
Short (prev mo.)3.66M
Technical
SMA 5078.57 (-15.2%)
SMA 20057.47 (+15.9%)
Beta1.25
S&P 52W Chg28.31%
Avg Vol (30d)530.51K
Avg Vol (10d)943.98K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—